Stock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval

Stock Track

08/07

Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.

The rally followed the company's announcement that its seasonal influenza vaccine, mFLUSIVA, has officially received U.S. Food and Drug Administration (FDA) approval. This marks the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. The approval covers use in adults aged 50 and above, with the vaccine expected to become available for the 2026-2027 respiratory virus season.

The clearance serves as a significant achievement for Moderna, coming after a period of rare public disagreement with FDA regulators. The vaccine is also currently under regulatory review in Australia, Canada, and Europe, suggesting potential for further upside from global commercialization.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1151684334"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151684334\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151684334?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151684334","market":"nz","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.</p><p>The rally followed the company's announcement that its seasonal influenza vaccine, mFLUSIVA, has officially received U.S. Food and Drug Administration (FDA) approval. This marks the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. The approval covers use in adults aged 50 and above, with the vaccine expected to become available for the 2026-2027 respiratory virus season.</p><p>The clearance serves as a significant achievement for Moderna, coming after a period of rare public disagreement with FDA regulators. The vaccine is also currently under regulatory review in Australia, Canada, and Europe, suggesting potential for further upside from global commercialization.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-08-07 22:41</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.</p><p>The rally followed the company's announcement that its seasonal influenza vaccine, mFLUSIVA, has officially received U.S. Food and Drug Administration (FDA) approval. This marks the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. The approval covers use in adults aged 50 and above, with the vaccine expected to become available for the 2026-2027 respiratory virus season.</p><p>The clearance serves as a significant achievement for Moderna, coming after a period of rare public disagreement with FDA regulators. The vaccine is also currently under regulatory review in Australia, Canada, and Europe, suggesting potential for further upside from global commercialization.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1151684334","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151684334","pubTimestamp":1786113661,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.The rally followed the company's announcement that its seasonal influenza...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"股票追踪|Moderna盘中飙升5.28%，首个mRNA流感疫苗获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.The rally followed the company's announcement that its seasonal influenza vaccine, mFLUSIVA, has officially received U.S. Food and Drug Administration (FDA) approval. This marks the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. The approval covers use in adults aged 50 and above, with the vaccine expected to become available for the 2026-2027 respiratory virus season.The clearance serves as a significant achievement for Moderna, coming after a period of rare public disagreement with FDA regulators. The vaccine is also currently under regulatory review in Australia, Canada, and Europe, suggesting potential for further upside from global commercialization.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}